In neoplastic liver diseases, the inhibition of PKM2 by either shikonin or compound 3k suppresses glycolysis and proliferation, induces apoptosis in HCC cells in vitro and enhances the antitumor effect of sorafenib in vivo [87,88,98]. The gene discussed is PKM; the disease is hepatocellular carcinoma.